EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna

View source ↗

Summary

The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Rheumatoid
• Leukemia Lymphocytic Chronic B-cell
• Lymphoma Non-hodgkin
• Microscopic Polyangiitis

Drugs mentioned

• Rituximab Mabion (rituximab)

Snippet

Status: Application withdrawn. Therapeutic area: Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid;Microscopic Polyangiitis. MAH: Mabion Spolka Akcyjna